CY1123666T1 - Φαρμακευτικες ενωσεις - Google Patents
Φαρμακευτικες ενωσειςInfo
- Publication number
- CY1123666T1 CY1123666T1 CY20201101096T CY201101096T CY1123666T1 CY 1123666 T1 CY1123666 T1 CY 1123666T1 CY 20201101096 T CY20201101096 T CY 20201101096T CY 201101096 T CY201101096 T CY 201101096T CY 1123666 T1 CY1123666 T1 CY 1123666T1
- Authority
- CY
- Cyprus
- Prior art keywords
- medicinal compounds
- compound
- formula
- cancer
- arylimidazolylisoxazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ένωση η οποία είναι ένα αρυλιμιδαζολυλο-ισοξαζόλιο του τύπου (Ι): (Τύπος (Ι)) ή ένα φαρμακευτικώς αποδεκτό άλας αυτού. Η ένωση έχει δραστικότητα διαμόρφωσης της δράσης της p300 και/ή της CBP και χρησιμοποιείται στη θεραπευτική αντιμετώπιση καρκίνου, ιδιαίτερα του καρκίνου του προστάτη.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1617630.7A GB201617630D0 (en) | 2016-10-18 | 2016-10-18 | Pharmaceutical compounds |
| PCT/GB2017/053152 WO2018073586A1 (en) | 2016-10-18 | 2017-10-18 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123666T1 true CY1123666T1 (el) | 2022-03-24 |
Family
ID=57680668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201101096T CY1123666T1 (el) | 2016-10-18 | 2020-11-19 | Φαρμακευτικες ενωσεις |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10696666B2 (el) |
| EP (1) | EP3529248B1 (el) |
| JP (1) | JP7152393B2 (el) |
| KR (1) | KR102578786B1 (el) |
| CN (1) | CN110049983B (el) |
| AU (1) | AU2017346453B2 (el) |
| BR (1) | BR112019007834A2 (el) |
| CA (1) | CA3039641A1 (el) |
| CY (1) | CY1123666T1 (el) |
| DK (1) | DK3529248T3 (el) |
| EA (1) | EA201990643A1 (el) |
| ES (1) | ES2828504T3 (el) |
| GB (1) | GB201617630D0 (el) |
| HR (1) | HRP20201444T1 (el) |
| HU (1) | HUE052443T2 (el) |
| IL (1) | IL266017B (el) |
| LT (1) | LT3529248T (el) |
| MX (1) | MX2019004113A (el) |
| PT (1) | PT3529248T (el) |
| RS (1) | RS61007B1 (el) |
| SG (1) | SG11201903155XA (el) |
| SI (1) | SI3529248T1 (el) |
| WO (1) | WO2018073586A1 (el) |
| ZA (1) | ZA201902334B (el) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201617627D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| TWI846350B (zh) | 2017-09-15 | 2024-06-21 | 美商佛瑪治療公司 | 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物 |
| GB201806320D0 (en) | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| US10870648B2 (en) | 2018-06-29 | 2020-12-22 | Forma Therapeutics, Inc. | Inhibiting CREB binding protein (CBP) |
| EP3937936A4 (en) * | 2019-03-15 | 2022-12-28 | Forma Therapeutics, Inc. | INHIBITION OF CYCLIC AMP-SENSITIVE ELEMENT BINDING PROTEIN (CREB) |
| CN112574189B (zh) * | 2019-09-27 | 2024-05-31 | 海创药业股份有限公司 | 一种ep300/cbp抑制剂 |
| CN112574178A (zh) * | 2019-09-27 | 2021-03-30 | 海创药业股份有限公司 | 一种氘代苯并咪唑类化合物及其作为ep300/cbp抑制剂的用途 |
| CN112574191B (zh) * | 2019-09-29 | 2024-01-23 | 南京圣和药业股份有限公司 | 异噁唑杂环类化合物及其应用 |
| EP4171556A1 (en) | 2020-06-25 | 2023-05-03 | Tolremo Therapeutics AG | A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc |
| CN115996717A (zh) | 2020-06-25 | 2023-04-21 | 托雷莫治疗股份公司 | 用于治疗癌症的cbp/p300溴结构域抑制剂和kras抑制剂的组合 |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| TW202227429A (zh) * | 2020-11-06 | 2022-07-16 | 大陸商貝達藥業股份有限公司 | Ｐ３００抑制劑、包含其的藥物組合物、其應用及製備其的方法 |
| WO2022138944A1 (ja) * | 2020-12-25 | 2022-06-30 | 国立研究開発法人国立がん研究センター | Ｓｗｉ／ｓｎｆ複合体機能異常がんの合成致死性に基づく治療法 |
| US20240109879A1 (en) * | 2020-12-31 | 2024-04-04 | Medshine Discovery Inc. | Benzimidazole compound and application thereof |
| WO2022184664A1 (en) | 2021-03-02 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| CN114989158A (zh) * | 2021-03-02 | 2022-09-02 | 复旦大学 | 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用 |
| EP4257130A1 (de) * | 2022-04-08 | 2023-10-11 | Justus-Liebig-Universität Gießen | Inobrodib zur behandlung von pulmonaler arterieller hypertonie |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL113472A0 (en) | 1994-04-29 | 1995-07-31 | Lilly Co Eli | Non-peptidyl tachykinin receptor antogonists |
| WO2001000213A1 (en) * | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| MXPA03003039A (es) | 2000-10-06 | 2003-10-15 | Neurogen Corp | Derivados de indola y bencimidazola como moduladores del receptor crf. |
| WO2002072549A1 (en) | 2001-03-12 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| ATE375350T1 (de) | 2002-02-21 | 2007-10-15 | Lilly Co Eli | Modulatoren von peroxisome proliferator- aktivierten rezeptoren |
| US7189716B2 (en) | 2003-01-03 | 2007-03-13 | Bristol-Myers Squibb Company | Tyrosine kinase inhibitors |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| WO2006124780A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| KR101486490B1 (ko) * | 2005-11-08 | 2015-01-27 | 제이더블유중외제약 주식회사 | α-헬릭스 유사체 및 암 줄기세포의 치료에 관한 방법 |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CN101616587A (zh) | 2006-12-05 | 2009-12-30 | 孙仲铭 | 吲唑化合物 |
| CN101687815A (zh) | 2007-06-26 | 2010-03-31 | 塞诺菲-安万特股份有限公司 | 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成 |
| CN101842098A (zh) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | 用于治疗病毒感染的含氮的二环化学实体 |
| EP2234487A4 (en) | 2007-12-19 | 2011-09-07 | Scripps Research Inst | ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE |
| US8501957B2 (en) | 2008-12-10 | 2013-08-06 | China Medical University | Benzimidazole compounds and their use as anticancer agents |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2011045415A2 (en) | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| WO2011085039A2 (en) * | 2010-01-05 | 2011-07-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| AU2011253143A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors |
| EP2397471A1 (en) | 2010-06-16 | 2011-12-21 | China Medical University | Benzimidazole compounds and their use |
| JP5850503B2 (ja) | 2010-09-14 | 2016-02-03 | 北海道公立大学法人 札幌医科大学 | 筋ジストロフィーを処置するための組成物 |
| EP2673269A1 (en) | 2011-02-09 | 2013-12-18 | F.Hoffmann-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| WO2012116440A1 (en) | 2011-03-03 | 2012-09-07 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| JP2014114212A (ja) | 2011-03-29 | 2014-06-26 | Dainippon Sumitomo Pharma Co Ltd | 新規ベンズイミダゾール誘導体 |
| TW201348231A (zh) | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
| BR112014030940B1 (pt) | 2012-06-11 | 2022-09-06 | UCB Biopharma SRL | Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| JP2016000697A (ja) | 2012-10-02 | 2016-01-07 | 大日本住友製薬株式会社 | ピリミジン誘導体 |
| JP2014073982A (ja) | 2012-10-03 | 2014-04-24 | Dainippon Sumitomo Pharma Co Ltd | 新規ベンズイミダゾール誘導体からなる医薬 |
| US9757379B2 (en) | 2012-11-14 | 2017-09-12 | The Board Of Regents Of The University Of Texas System | Inhibition of HIF-2α heterodimerization with HIF1β (ARNT) |
| WO2014157382A1 (ja) | 2013-03-29 | 2014-10-02 | 味の素株式会社 | スフィンゴシンキナーゼ阻害剤 |
| PL231063B1 (pl) | 2013-04-10 | 2019-01-31 | Oncoarendi Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia | Pochodne 1-(podstawionej sulfonylo)-2-aminoimidazoliny jako środki przeciwnowotworowe |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| JP6461118B2 (ja) * | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
| WO2015023958A1 (en) | 2013-08-15 | 2015-02-19 | The University Of Kansas | Toll-like receptor agonists |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| CN106879256B (zh) | 2014-07-31 | 2021-08-03 | 韩国巴斯德研究所 | 2-氨基-苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素e合成酶抑制剂的应用 |
| JP6771464B2 (ja) * | 2014-11-27 | 2020-10-21 | ジェネンテック， インコーポレイテッド | Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物 |
| GB201506658D0 (en) * | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) * | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2016200401A1 (en) | 2015-06-12 | 2016-12-15 | Transitions Optical, Inc. | Alignment compounds |
| JP6912039B2 (ja) | 2015-08-12 | 2021-07-28 | ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ | 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用 |
| EP3355871A1 (en) | 2015-10-02 | 2018-08-08 | Gilead Sciences, Inc. | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| AU2016367914A1 (en) | 2015-12-11 | 2018-06-28 | The Board Of Regents Of The University Of Texas System | Substituted benzimidazolium, pyrido-imidazolium, or pyrazino-imidazolium compounds as chemotherapeutics |
| WO2017106568A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer |
| US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| EP3471726A4 (en) | 2016-06-21 | 2019-10-09 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US20180179191A1 (en) | 2016-11-22 | 2018-06-28 | Gilead Sciences, Inc. | Synthesis of a compound that modulates the activity of bromodomain-containing proteins |
-
2016
- 2016-10-18 GB GBGB1617630.7A patent/GB201617630D0/en not_active Ceased
-
2017
- 2017-10-18 BR BR112019007834A patent/BR112019007834A2/pt unknown
- 2017-10-18 HU HUE17790813A patent/HUE052443T2/hu unknown
- 2017-10-18 MX MX2019004113A patent/MX2019004113A/es unknown
- 2017-10-18 JP JP2019520588A patent/JP7152393B2/ja active Active
- 2017-10-18 EP EP17790813.4A patent/EP3529248B1/en active Active
- 2017-10-18 RS RS20201314A patent/RS61007B1/sr unknown
- 2017-10-18 CA CA3039641A patent/CA3039641A1/en active Pending
- 2017-10-18 CN CN201780072401.XA patent/CN110049983B/zh active Active
- 2017-10-18 EA EA201990643A patent/EA201990643A1/ru unknown
- 2017-10-18 US US16/341,631 patent/US10696666B2/en active Active
- 2017-10-18 LT LTEP17790813.4T patent/LT3529248T/lt unknown
- 2017-10-18 ES ES17790813T patent/ES2828504T3/es active Active
- 2017-10-18 SI SI201730402T patent/SI3529248T1/sl unknown
- 2017-10-18 PT PT177908134T patent/PT3529248T/pt unknown
- 2017-10-18 WO PCT/GB2017/053152 patent/WO2018073586A1/en unknown
- 2017-10-18 AU AU2017346453A patent/AU2017346453B2/en active Active
- 2017-10-18 DK DK17790813.4T patent/DK3529248T3/da active
- 2017-10-18 SG SG11201903155XA patent/SG11201903155XA/en unknown
- 2017-10-18 KR KR1020197014352A patent/KR102578786B1/ko active IP Right Grant
-
2019
- 2019-04-12 ZA ZA2019/02334A patent/ZA201902334B/en unknown
- 2019-04-14 IL IL266017A patent/IL266017B/en unknown
-
2020
- 2020-05-14 US US15/931,782 patent/US11377443B2/en active Active
- 2020-09-10 HR HRP20201444TT patent/HRP20201444T1/hr unknown
- 2020-11-19 CY CY20201101096T patent/CY1123666T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110049983A (zh) | 2019-07-23 |
| GB201617630D0 (en) | 2016-11-30 |
| US11377443B2 (en) | 2022-07-05 |
| HUE052443T2 (hu) | 2021-04-28 |
| EP3529248B1 (en) | 2020-08-19 |
| IL266017B (en) | 2021-08-31 |
| CN110049983B (zh) | 2022-06-14 |
| US10696666B2 (en) | 2020-06-30 |
| SI3529248T1 (sl) | 2020-11-30 |
| ES2828504T3 (es) | 2021-05-26 |
| PT3529248T (pt) | 2020-09-03 |
| KR20190075095A (ko) | 2019-06-28 |
| MX2019004113A (es) | 2019-09-09 |
| AU2017346453B2 (en) | 2022-02-17 |
| DK3529248T3 (da) | 2020-09-14 |
| IL266017A (en) | 2019-06-30 |
| EP3529248A1 (en) | 2019-08-28 |
| JP7152393B2 (ja) | 2022-10-12 |
| US20200407349A1 (en) | 2020-12-31 |
| ZA201902334B (en) | 2022-10-26 |
| JP2019537571A (ja) | 2019-12-26 |
| HRP20201444T1 (hr) | 2020-12-11 |
| BR112019007834A2 (pt) | 2019-07-16 |
| LT3529248T (lt) | 2020-10-26 |
| EA201990643A1 (ru) | 2019-11-29 |
| KR102578786B1 (ko) | 2023-09-15 |
| US20190375740A1 (en) | 2019-12-12 |
| AU2017346453A1 (en) | 2019-05-02 |
| WO2018073586A1 (en) | 2018-04-26 |
| CA3039641A1 (en) | 2018-04-26 |
| RS61007B1 (sr) | 2020-11-30 |
| SG11201903155XA (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123666T1 (el) | Φαρμακευτικες ενωσεις | |
| CY1124810T1 (el) | Συνδυαστικη θεραπεια για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| CO2019008487A2 (es) | Compuesto de quinazolina | |
| CY1125214T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1124055T1 (el) | Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες | |
| CY1123475T1 (el) | Αναστολεις της ειδικης για λυσινη απομεθυλασης-1 | |
| CY1125127T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1120619T1 (el) | Χημικες οντοτητες | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| CY1120173T1 (el) | Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης | |
| EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| CY1121554T1 (el) | Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112018068412A2 (pt) | composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral | |
| CY1120095T1 (el) | Αναστολεις της erk και μεθοδοι χρησης | |
| CY1121722T1 (el) | Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| CY1122971T1 (el) | Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων |